RECRUITING

Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Study Aims Pilot study: Due to the large recruitment goal and length of the project, the study team/PIs will evaluate the first cohort of 6-10 participants to refine study procedures and study-related materials. If no major modifications are made to the protocol as a result of this evaluation, data from these participants will be included for analysis. Aim 1: Evaluate the efficacy of an early, evidence-based, clinical experience-based therapeutic intervention (from the NICU to 12-months corrected age) on improving motor function and reducing severity of motor delays in infants at 12-months corrected age. The investigators hypothesize that the intervention group will demonstrate an average 8-point difference (0.5 standard deviation) compared to the standard of care group. \[an 8-point difference is considered a clinically meaningful difference\] Aim 2: Evaluate the early effects (i.e., before 12 months) of a therapeutic intervention, provided from NICU to 12-months corrected age, on motor function and severity of motor delay. The Investigators hypothesize that a statistically significant higher percentage of infants in the intervention group will demonstrate improved motor function and reduced severity of motor delays, compared to the standard of care group-assessed using sensors, the NSMDA and TIMP-as early as 3-months corrected age. Aim 3: Evaluate whether an early intervention that focuses on caregiver engagement improves caregiver well-being. The invetigators hypothesize that an intervention that focuses on supporting and addressing the individual needs of the caregiver will improve caregiver well-being. The investigators will evaluate these effects using the PedsQL (Family Impact Module).

Official Title

Early Detection and Therapeutic Improvement of Motor Delay in High Risk Infants: A Randomized, Controlled Trial

Quick Facts

Study Start:2022-10-01
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05568264

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:33 Weeks to 48 Weeks
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * BW \<1500 grams
  2. * Disorders of the central nervous system
  3. * Brain injury (including but not limited to extra axial hemorrhage, any grade intraventricular or intraparenchymal hemorrhage, stroke, hypoxic ischemic encephalopathy (HIE), meningitis)
  4. * HIE includes mild, moderate, severe exam on modified Sarnat exam, both cooled and non-cooled
  5. * includes "at risk for HIE" with 10-minute Apgar \<7 plus pH\<7.15 or base deficit \>/=12.
  6. * Brain developmental abnormalities (hydrocephalus, microcephaly, cortical dysgenesis)
  7. * Cramped synchronous movements at term PMA
  8. * Bronchopulmonary dysplasia (BPD) defined as need for respiratory support at 36 weeks postmenstrual age in an infant born at \<32 weeks of gestation.
  9. * Medically stable AND able to start intervention between 34-48 weeks PMA.
  1. * open wounds, skin condition precluding sensor placement
  2. * immune deficiencies requiring protective isolation
  3. * limb reduction defects
  4. * followed primarily in another clinic (including but not limited to meningomyelocele and related conditions/trisomy 21)
  5. * bleeding disorders or ongoing need for anticoagulation
  6. * palliative or hospice care (for life limiting conditions including, but not limited to trisomy 18, 13)
  7. * known visual impairment at the time of enrollment
  8. * DCFS custody
  9. * no English-speaking caregivers
  10. * any other condition that would preclude participation in the study, as determined by the PI
  11. * previously enrolled in competing randomized trial with developmental outcome variables

Contacts and Locations

Study Contact

Elizabeth Hoffman, DPT
CONTACT
312-238-7711
ehoffman@sralab.org
Sara Prokup, DPT
CONTACT
312-238-1355
sprokup@sralab.org

Principal Investigator

Arun Jayaraman, PT, PhD
PRINCIPAL_INVESTIGATOR
Shirley Ryan AbilityLab

Study Locations (Sites)

Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
United States
Northwestern Medicine Prentice Children's Hospital
Chicago, Illinois, 60611
United States
Children's Hospital at the University of Illinois
Chicago, Illinois, 60612
United States

Collaborators and Investigators

Sponsor: Shirley Ryan AbilityLab

  • Arun Jayaraman, PT, PhD, PRINCIPAL_INVESTIGATOR, Shirley Ryan AbilityLab

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-01
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2022-10-01
Study Completion Date2026-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Motor Delay
  • Premature Birth
  • Intraventricular Hemorrhage
  • Hypoxic-Ischemic Encephalopathy
  • Bronchopulmonary Dysplasia